Compare Eli Lilly And Co (LLY) vs Teradyne, Inc. (TER) Price & Performance

Eli Lilly (LLY) trades at $1,179.27, down 0.79% on the day, with a bullish technical outlook and strong fundamental momentum. The stock has consistently beaten earnings estimates, with Q2 2026 EPS of $8.38 surpassing the $6.40 expectation. Revenue surged to $65.18 billion in 2025, driving a net income margin of 33.53%. Recent news highlights promising pipeline developments in weight-loss and diabetes drugs, reinforcing its market leadership.

The outlook remains positive given robust revenue growth, high profitability, and analyst consensus favoring buys. Key risks include competitive pressures in the obesity drug market and execution challenges in scaling production. With a consensus price target of $1,350, representing ~14% upside, the stock offers growth potential but requires monitoring of pipeline progress and market dynamics.

Teradyne (TER) trades at $402.68, down 2.21% on the day, but maintains a bullish technical outlook with strong support near $388. The company reported robust earnings beats in recent quarters, with Q2 2026 EPS of $2.47 surpassing the $2.09 estimate. Revenue growth is accelerating, projected to reach $4.5 billion in 2026, while net income margins are expected to expand to 25.76%. Recent developments include the launch of the Magnum E2 memory test system and Iris 100 for microLED devices, positioning TER to capitalize on AI and high-performance computing demand.

The investment outlook for TER is positive, driven by strong fundamentals, analyst optimism, and strategic positioning in semiconductor test equipment. Key opportunities include exposure to AI-driven demand and consistent earnings outperformance. Risks involve competitive pressures from firms like KLAC and COHU, cyclical semiconductor industry dynamics, and execution risks in new product launches. With a consensus price target of $461.50 and no sell ratings, Wall Street sentiment remains bullish, though valuation multiples are elevated.